Arcutis Biotherapeutics (NASDAQ: ARQT) insider transactions

In the twelve months to 10 November 2026, executives and directors of Arcutis Biotherapeutics reported 70 open-market sales of 553,600 shares ($14.9m) and 0 open-market purchases, by 11 people, according to the Form 4 filings they submitted to the SEC.

Latest transactions

The 20 most recent transactions in Arcutis Biotherapeutics shares reported on Form 4
Date	Insider	Role	Transaction	Shares	Price	Held after	Filing
4 November 2026	Matsuda Masaru	EVP, Chief Legal Officer	Option exercise, 10b5-1 plan	+40,000	$3.64	151,289	Form 4
4 November 2026	Matsuda Masaru	EVP, Chief Legal Officer	Open-market sale, 10b5-1 plan	−40,000	$34.32	111,289	Form 4
2 November 2026	Watanabe Todd	See Remarks	Open-market sale	−4,377	$31.86	712,826	Form 4
2 November 2026	Burnett Patrick	EVP, Chief Medical Officer	Open-market sale	−943	$31.86	116,649	Form 4
2 November 2026	Matsuda Masaru	EVP, Chief Legal Officer	Open-market sale, 10b5-1 plan	−1,219	$31.86	111,289	Form 4
23 October 2026	Scott Robert A	Director	Grant or award	+2,819	—	2,819	Form 4
15 October 2026	Welgus Howard G.	Director	Option exercise, 10b5-1 plan	+822	$6.52	36,663	Form 4
15 October 2026	Welgus Howard G.	Director	Option exercise, 10b5-1 plan	+1,018	$7.51	37,681	Form 4
15 October 2026	Welgus Howard G.	Director	Option exercise, 10b5-1 plan	+2,254	$8.63	39,935	Form 4
15 October 2026	Welgus Howard G.	Director	Open-market sale, 10b5-1 plan	−4,728	$26.93	35,207	Form 4
16 September 2026	Matsuda Masaru	See Remarks	Open-market sale, 10b5-1 plan	−3,674	$25.00	112,508	Form 4
15 September 2026	Welgus Howard G.	Director	Option exercise, 10b5-1 plan	+822	$6.52	37,297	Form 4
15 September 2026	Welgus Howard G.	Director	Option exercise, 10b5-1 plan	+1,019	$7.51	38,316	Form 4
15 September 2026	Welgus Howard G.	Director	Option exercise, 10b5-1 plan	+2,255	$8.63	40,571	Form 4
15 September 2026	Welgus Howard G.	Director	Open-market sale, 10b5-1 plan	−4,730	$24.18	35,841	Form 4
8 September 2026	Matsuda Masaru	See Remarks	Open-market sale, 10b5-1 plan	−9,989	$25.03	116,182	Form 4
27 August 2026	Curran Terrie	Director	Option exercise	+11,148	$7.51	34,674	Form 4
27 August 2026	Curran Terrie	Director	Open-market sale	−11,148	$25.03	23,526	Form 4
27 August 2026	Curran Terrie	Director	Option exercise	+27,052	$8.63	50,578	Form 4
27 August 2026	Curran Terrie	Director	Open-market sale	−27,052	$25.03	23,526	Form 4

Names appear as in the filing, surname first. A dash in the price column means the filing reports none, as in grants and gifts.

How to read the table

Only open-market purchases and sales are trades the insider chose to make at the market price, and they are the ones counted in the summary above. Grants, option exercises and shares withheld for tax come from pay plans. A sale marked as a 10b5-1 plan was scheduled in advance under a written plan.

Where each row comes from

From the Form 4 that each executive, director or large shareholder must file with the SEC within two business days of a transaction, read up to 10 November 2026. Each row links to its filing on EDGAR. Only transactions in shares are listed, not derivatives, and amended filings are left out. The accounts of the company are on the Arcutis Biotherapeutics page; the method, in data sources.

Information prepared from the Form 4 filings submitted to the SEC, for information purposes only. It is not financial advice or a recommendation to buy or sell. Updated on 12 November 2026.